

India Equity Research | Oil & Gas June 10, 2021 **Result Update** 

# Petronet LNG

Refer to important disclosures at the end of this report

# Dahej volumes better than expected; significant capex lined up

- Q4FY21 standalone EBITDA/PAT of Rs10.91bn/6.23bn were up 56%/74% yoy and down 18%/29% qoq but 3% above/8% below our estimates. Volumes were a 6% beat. The PAT miss was due to lower Other Income (down 43% yoy/56% qoq) and higher ETR of 27%.
- The Dahej terminal operated at 93% capacity, above our 88% est. Long-term/spot/tolling volumes fell 10%/was flat/fell 7% qoq to 102tbtu/5tbtu/97tbtu. Kochi utilization was 22% (21% est.). EBITDA/mmbtu fell 12% qoq to Rs50.1 (2% miss, up 57% yoy).
- Management stated Rs52bn of core capex in next five years, along with Rs40bn/80bn in compressed biogas/LNG retail, which are promising sectors but with low earnings visibility. Weak Q1FY22 utilization and offtakers asking for Dahej tariff in Kochi are dampeners.
- We cut FY22/23E EPS by 13%/11%, assuming lower volumes and Kochi tariffs. We also increase WACC and capex though not building retail/CBG into our earnings model. We hence lower our DCF-based TP by 15% to Rs290. Maintain Buy but with EW stance.

**Q4FY21 highlights:** Other Expenditure jumped 39% qoq to Rs1.6bn (down 61% yoy but 33% above est.) due to Rs180mn of forex loss and Rs560mn on CSR. Employee cost, interest and depreciation were also somewhat higher than our expectations. Total volumes were flat yoy/down 7% qoq at 218tbtu. Implied marketing margin on spot LNG is estimated at USD2.2/mmbtu. Four years of use or pay charges totaling Rs1.98bn (ex GST) invoked against three tolling users had been booked but only Rs545mn has been paid so far. Discussions are on, and PLNG expects resolution with no material impact. For FY21, PLNG's EBITDA/APAT stood at RsRs47.0bn/29.5bn, up 18% each with a 22% jump in EBITDA/mmbtu and a 17% reduction in interest cost. Volume declined 3% yoy. The board recommended Rs3.5/sh final dividend, with total of Rs11.5/sh, implying 58% payout (70% in FY20). Share of profits from assoc./JVs increased from Rs147.5mn in FY20 to Rs189.3mn in FY21 (Rs145.5mn in Q4).

**Guidance**: April-May'21 Dahej utilization had been weak due to lockdown. Currently, it has recovered to 88% utilization. PLNG wants higher Kochi volumes for lowering tariffs. The Bangalore pipeline is progressing, with only 250km stretch from Coimbatore is pending (will take 1.5 years to complete). Dividend payout in FY21 was slightly down as PLNG has huge growth capex plans and wants to build reserves. Capex target for FY22/23 is Rs5.3bn/10bn+. PLNG wants to go mostly alone in LNG retail, with 3.5mmtpa volume target by CY30 from 1,000+ stations. 80 CBG Lols have been received from OMCs-CGDs. A new Kochi tank is planned to benefit from market arbitrage. Sri Lanka terminal is dampened by new proposal to set up deep sea FSRU.

**Valuation:** Our Rs290 TP implies a 15.0x FY23E target PE multiple. Key risks are adverse petroleum/gas prices, slowdown, competition and capital misallocation.

Please see our sector model portfolio (Emkay Alpha Portfolio): Oil & Gas (Page 9)

#### Financial Snapshot (Standalone)

(Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Revenue	354,520	260,229	349,187	405,502	418,251
EBITDA	42,659	46,995	44,124	48,947	51,794
EBITDA Margin (%)	12.0	18.1	12.6	12.1	12.4
APAT	25,875	29,494	27,530	30,621	31,631
EPS (Rs)	17.2	19.7	18.4	20.4	21.1
EPS (% chg)	15.8	14.0	(6.7)	11.2	3.3
ROE (%)	27.9	26.1	22.6	22.8	21.2
P/E (x)	13.2	11.6	12.5	11.2	10.8
EV/EBITDA (x)	8.2	7.1	7.3	6.4	5.8
P/BV (x)	3.1	2.9	2.7	2.4	2.2

Source: Company, Emkay Research



СМР	Target Price
Rs 229 as of (June 9, 2021)	Rs 290 (▼) 12 months
Rating	Upside
BUY (∎)	26.8 %

## Change in Estimates

EPS Chg FY22E/FY23E	(%)	(13)/(11)
Target Price change (%)		(14.7)
Target Period (Months)		12
Previous Reco		BUY
Emkay vs Consensus		
EPS Estim	ates	
	FY22E	FY23E
Emkay	18.4	20.4
Consensus	21.7	23.6
Mean Consensus TP (12	2M)	Rs 306
Stock Details		
Bloomberg Code		PLNG IN
Face Value (Rs)		10
Shares outstanding (mn	)	1,500
52 Week H/L		275 / 201
M Cap (Rs bn/USD bn)	3	343 / 4.70
Daily Avg Volume (nos.)		3,912,447
Daily Avg Turnover (US	\$mn)	12.6
Shareholding Pattern I	Mar '21	
Promoters		50.0%
Flls		30.5%
DIIs		6.3%
Public and Others		13.2%
-		
Price Performance		13.2%
Price Performance (%) 1M 3M		13.2%
Price Performance(%)1MAbsolute(6)(9)	) (11	13.2% 1 12M ) (9)
Price Performance(%)1M3MAbsolute(6)(9)Rel. to Nifty(11)(12)	) (11	13.2% 1 12M ) (9)
Price Performance(%)1MAbsolute(6)(9)Rel. to Nifty(11)Relative price chart	) (11	13.2% 1 12M ) (9) ) (41)
Price Performance         (%)       1M       3M         Absolute       (6)       (9)         Rel. to Nifty       (11)       (12)         Relative price chart       275       Rs	) (11	13.2% <b>1 12M</b> ) (9) ) (41) <sup>%</sup> [ <sup>10</sup>
Price Performance (%) 1M 3M Absolute (6) (9 Rel. to Nifty (11) (12 Relative price chart 275 260 Rs	) (11	13.2% 1 12M ) (9) ) (41)
Price Performance         (%)       1M       3M         Absolute       (6)       (9)         Rel. to Nifty       (11)       (12)         Relative price chart       275       Rs	) (11	13.2% <b>1 12M</b> ) (9) ) (41) <sup>%</sup> [ <sup>10</sup>
Price Performance (%) 1M 3M Absolute (6) (9 Rel. to Nifty (11) (12 Relative price chart 275 260 Rs	) (11	13.2% 1 12M ) (9) ) (41) %  10 0
Price Performance (%) 1M 3M Absolute (6) (9 Rel. to Nifty (11) (12 Relative price chart 275 260 245 Rs 245	) (11	13.2% 13.2% 1 12M ) (9) ) (41) % [10 0 -10
Price Performance           (%)         1M         3N           Absolute         (6)         (9)           Rel. to Nifty         (11)         (12)           Relative price chart         275         260           245         Rs         400           230         100         100           215         200         100	) (11 ) (23	13.2% 1 12M ) (9) ) (41)
Price Performance (%) 1M 3M Absolute (6) (9 Rel. to Nifty (11) (12 Relative price chart 275 260 245 230 215	) (11 ) (23	13.2% 1 12M ) (9) ) (41)
Price Performance           (%)         1M         3M           Absolute         (6)         (9)           Rel. to Nifty         (11)         (12)           Relative price chart         275         260           245         Assolute         (11)           245         Assolute         (11)           245         Assolute         (11)           215         Assolute         (11)           200         Jun-20 Aug-20 Oct-20 Dec-20         Jun-20 Aug-20 Oct-20 Dec-20	) (11 ) (23	13.2% 1 12M ) (9) ) (41) % 10 -10 -20 -30 -30 -40 r-21 Jun-21
Price Performance (%) 1M 3M Absolute (6) (9 Rel. to Nifty (11) (12 Relative price chart 275 260 245 200 215 200 Jun-20 Aug-20 Oct-20 Dec-20 Petronet LNG (LHS)	) (11 ) (23	13.2% 1 12M ) (9) ) (41) % 10 -10 -20 -30 -40 -7-21 Jun-21 to Nifty (RHS) Global. The
Price Performance (%) 1M 3M Absolute (6) (9 Rel. to Nifty (11) (12 Relative price chart 275 260 245 200 215 200 Jun-20 Aug-20 Oct-20 Dec-20 Petronet LNG (LHS) Source: Bloomberg This report is solely produced following person(s) are respon	) (11 ) (23	13.2% 1 12M ) (9) ) (41) % 10 -10 -20 -30 -40 -7-21 Jun-21 to Nifty (RHS) Global. The
Price Performance (%) 1M 3M Absolute (6) (9 Rel. to Nifty (11) (12 Relative price chart 275 260 245 200 Jun-20 Aug-20 Oct-20 Dec-20 Peronet LNG (LHS) Source: Bloomberg This report is solely produced following person(s) are respon production of the recommendant	) (11 ) (23	13.2% 13.2% 12M ) (9) ) (41) % -10 -20 -30 -40 r-21 Jun-21 to Nifty (RHS) Colobal. The he
Price Performance (%) 1M 3M Absolute (6) (9 Rel. to Nifty (11) (12 Relative price chart 275 260 245 200 245 200 Jun-20 Aug-20 Oct-20 Dec-20 Petronet LNG (LHS) Source: Bloomberg This report is solely produced following person(s) are respon production of the recommenda Sabri Hazarika	) (11 ) (23	13.2% 13.2% 12M ) (9) ) (41) % -10 -20 -30 -40 r-21 Jun-21 to Nifty (RHS) Colobal. The he
Price Performance (%) 1M 3M Absolute (6) (9 Rel. to Nifty (11) (12 Relative price chart 275 260 245 200 215 200 215 200 Petronet LNG (LHS) Source: Bloomberg This report is solely produced following person(s) are respon production of the recommender Sabri Hazarika sabri.hazarika@emkayg	) (11 ) (23 ) (23 ) (23 ) (23 ) (23) ) (23) ) (24) ) (24) ) (24) ) (24) ) (24) ) (25) ) (25)	13.2% 13.2% 12M (9) (9) (41) (41) (41) (41) (41) (41) (41) (41) (41) (5) (6) (6) (7) (7) (7) (7) (7) (7) (7) (7

+91 22 6612 1336

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# Exhibit 1: Actual vs. Estimates (Q4FY21)

De una	A	Estimates	Consensus	Vari	ation	0
Rs mn	Actual	(Emkay)	Estimates (Bloomberg)	Emkay	Consensus	Comment
Total Revenue	75,753	82,023	88,204	-8%	-14%	
EBITDA	10,911	10,553	11,437	3%	-5%	Due to better volumes, higher gross profit
EBITDA Margin (%)	14%	13%	13%	154bps	144bps	
Net Profit	6,234	6,745	7,262	-8%	-14%	Due to lower Other Income and higher ETR

Source: Company, Emkay Research

## Exhibit 2: Quarterly summary

Rs mn	Q4FY20	Q1FY21	Q2FY21	Q3FY21	Q4FY21	YoY	QoQ	FY20	FY21	YoY
Net sales	80,442	43,836	55,578	67,212	70,533	-12%	5%	331,190	237,159	-28%
Regas service income^	5,230	5,000	6,780	6,070	5,220	0%	-14%	23,330	23,070	-1%
Total revenue	85,672	48,836	62,358	73,282	75,753	-12%	3%	354,520	260,229	-27%
Raw material cost	74,360	38,365	47,199	58,434	62,817	-16%	8%	304,959	206,815	-32%
Employee cost	289	360	338	343	430	49%	25%	1,258	1,471	17%
Other expenses	4,048	1,011	1,188	1,152	1,596	-61%	39%	8,408	4,948	-41%
Total expenditure	78,696	39,736	48,726	59,929	64,842	-18%	8%	314,625	213,234	-32%
EBITDA	6,975	9,099	13,632	13,353	10,911	56%	-18%	39,895	46,995	18%
Depreciation	1,942	1,936	1,952	1,925	2,028	4%	5%	7,761	7,841	1%
EBIT	5,033	7,164	11,680	11,428	8,883	76%	-22%	32,134	39,155	22%
Interest cost	1,035	881	850	815	813	-21%	0%	4,032	3,360	-17%
Other income	865	684	1,596	1,111	492	-43%	-56%	3,726	3,882	4%
PBT before exceptional	4,863	6,966	12,426	11,724	8,561	76%	-27%	31,827	39,677	25%
Exceptional items	-	-	-	-	-			-721	-	
PBT	4,863	6,966	12,426	11,724	8,561	76%	-27%	31,107	39,677	28%
Current tax	1,650	1,880	3,070	2,960	2,340	42%	-21%	8,600	10,250	19%
Deferred tax	-378	-116	83	-21	-13			-4,470	-67	
Total tax	1,272	1,764	3,153	2,939	2,328	83%	-21%	4,131	10,183	147%
Reported PAT	3,590	5,202	9,273	8,785	6,234	74%	-29%	26,976	29,494	9%
Rep. EPS (Rs.)	2.4	3.5	6.2	5.9	4.2	74%	-29%	18.0	19.7	9%
Adjusted PAT	5,643	5,202	9,273	8,785	6,234	10%	-29%	24,963	29,494	18%
Adj. EPS (Rs.)	3.8	3.5	6.2	5.9	4.2	10%	-29%	16.6	19.7	18%
Shares O/S (mn)	1,500	1,500	1,500	1,500	1,500	0%	0%	1,500	1,500	0%
EBITDA margin	8%	19%	22%	18%	14%			11%	18%	
NPM	4%	11%	15%	12%	8%			8%	11%	
Effective tax rate	26%	25%	25%	25%	27%			13%	26%	
Dahej Utilization	93%	82%	109%	<b>99%</b>	93%			103%	96%	
Dahej Volumes (mmt)	4.1	3.6	4.8	4.4	4.0	-1%	-8%	17.4	16.7	-4%
Long Term (tbtu)	95	78	103	113	102	7%	-10%	406	396	-2%
3rd Party Regas (tbtu)	105	100	135	104	97	-8%	-7%	454	436	-4%
Spot LNG (tbtu)	6	3	5	5	5	-17%	0%	25	18	-28%
Kochi Utilization	21%	14%	17%	20%	22%			17%	19%	
Kochi Volumes (mmt)	0.3	0.2	0.2	0.3	0.3	8%	8%	0.8	0.9	9%
Long Term (tbtu)	11	8	8	8	11	0%	38%	32	35	9%
3rd Party Regas (tbtu)	-	-	-	3	1			4	4	0%
Spot LNG (tbtu)	2	1	3	2	2	0%	0%	7	8	14%
Total Volumes (tbtu)	219	190	254	235	218	0%	-7%	928	897	-3%
Regas Tariff (Rs./mmbtu)										
Dahej	51.7	51.7	51.7	51.7	54.3	5%	5%	49.9	52.4	5%
Kochi	79.1	83.1	83.1	83.1	83.1	5%	0%	79.1	83.1	5%
Services Regas Tariff (Rs./mmbtu) ^	49.8	50.0	50.2	56.7	53.3	7%	-6%	51.0	52.6	3%
Cal. MM (USD/mmbtu)	0.5	1.9	3.5	3.9	2.2	364%	-45%	1.5	3.0	103%
EBITDA/mmbtu (Rs.)	31.9	47.9	53.7	56.8	50.1	57%	-12%	43.0	52.4	22%
Avg. real. (USD/mmbtu)	9.7	6.4	6.3	7.1	8.0	-17%	13%	9.9	7.0	-30%

\*Note: Adjusted numbers may not match with annual tables fully due to different adjustment method in Emkay detailed annual model

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# Exhibit 3: Changes in assumptions

	FY22E			FY23E			FY24E
	Old	New	% Chg.	Old	New	% Chg.	Introduced
EBITDA/mmbtu (Rs.)	51.3	48.4	-6%	52.0	49.4	-5%	51.0
Blended Regas Tariff (Rs/mmbtu)	62.1	59.3	-4%	64.0	61.1	-5%	62.8
Volumes (mmt)	18.8	17.9	-5%	19.7	19.4	-1%	19.9
Growth	8%	2%	-624bps	5%	9%	405bps	2%

Source: Emkay Research

#### Exhibit 4: Changes in estimates

		FY22E			FY23E		FY24E
Rs mn	Old	New	% Chg.	Old	New	% Chg.	Introduced
Revenue	353,654	349,187	-1%	383,754	405,502	6%	418,251
EBITDA	49,059	44,124	-10%	52,143	48,947	-6%	51,794
EBITDA Margins	14%	13%	-124bps	14%	12%	-152bps	12%
PAT	31,621	27,530	-13%	34,295	30,621	-11%	31,631
EPS (Rs)	21.1	18.4	-13%	22.9	20.4	-11%	21.1

Source: Emkay Research

# **Con-call highlights**

- Volume-wise, March 2021 was good. Prices were higher but long-term LNG was USD1.5/mmbtu below spot and had done well. Indian customers are price sensitive. April-May'2021 utilization (in Dahej) had been weak due to lockdown, lower demand and higher prices. June saw it recovering to 88% utilization.
- New domestic gas can impact spot and short-term LNG volumes in the near term, but eventually gas demand will be much higher (70-90mmtpa in CY30 vs. 46mmtpa now). Gas ceiling is expected to go up to USD5-6/mmbtu in the next revision. Dahej is booked up to 16mmtpa. Spot volumes (less now) would rise as prices correct.
- Kochi terminal users are asking for regas tariffs equivalent to Dahej though PLNG wants tariff cut to be met by higher volumes (now only 3-4mmscmd, hence not possible). Expect some solution this quarter. The company took 5% hike in April vs. Rs83.1/mmbtu in FY21.
- Kochi is expected to hit 25-30% utilization along/by 6M-YE 2021. Higher spot LNG prices have affected ramp-up now. FACT cannot operate at higher than USD8/mmbtu whereas spot is more than USD10 now. GAIL's Bangalore pipeline is progressing with only 250km of Coimbatore-Bangalore stretch pending and will take 1-1.5 years to complete.
- The use or pay was invoked on tolling customers, where 2 out of 3 have not paid but as per contracts are liable. Discussions are on, and will be resolved shortly, maybe by this quarter.
- Dividend payout in FY21 was down to 58% from 70% last year as the company has huge growth capex plans in next five years and wants to build reserves. Capex target for FY22/23 is Rs5.3bn/10bn+ though FY23 can see revision based on new plans (will come up with new guidance).
- Capex includes two tanks at Dahej for Rs12.4bn (will come by CY24), a third jetty for Rs17.0bn (by CY25), capacity expansion to 20/22.5mmtpa for Rs2.2bn/8.9bn, 14 tanker loading bays in both terminals for Rs4bn, new tank in Kochi for Rs7bn and East Coast terminal at Gopalpur for Rs15.4bn.
- PLNG is also looking at Rs80bn capex in LNG retail over next 5+ years. It plans to set 20-30/300/1,000 LNG stations across highways in 1-2/3-4/5+ years. There is a change in thought process to go mostly alone as PNGRB has given clearance and wants to earn retail margins. Some tie-ups with OMCs-CGDs could be there.
- 1,200kms radius of virtual pipeline can be set and economics is favorable. LNG is 25-40% cheaper than diesel. Initially, payback will be longer (less than 5 years in steady state) and offtake low but market will develop. 50 stations are inaugurated. PLNG targets 3.5mmtpa volumes by CY30. Commitment is there. STCs are also interested.
- It is also looking at Rs40bn capex in CBG in three years and has signed a deal with MOPNG for 100 projects-plants. CBG offtake is guaranteed by OMCs-CGDs at an attractive Rs46/kg price (USD11-12/mmbtu). They have issued Lols and 80 have been received. Four stations would come up in Haryana. It will take time but can be sustainable.
- The new Kochi tank is to benefit from market arbitrage, as in, buy own cargoes and store at right prices and sell at profits. Generally, cargoes are stored up to a month but under this venture would see further.
- Dahej 22.5mmtpa expansion is committed capex while DFR for jetty has also been received. PLNG has to work out plans in LNG stations-retail, including land availability, hence it may see some deviation. Rs150bn+ of capex in five years imply Rs20-30bn+ annual phasing in 2-3 years. There no overseas capex plans as of now; all are focused on India.
- Sri Lanka now wants a 5km deep-sea FSRU vs. shore-based earlier, which has become challenging and dampened interest. The company however did not say global projects are on backburner now.

- Recent Qatargas-Sinopec term etc. contracts have been done at 10-10.2% slope to oil; hence, PLNG when sourcing again will look for 10% or less. LNG is widely available now and does not have any overseas project interest.
- Q4FY21 had also Rs180mn of forex loss, while Rs560mn additional was on CSR qoq. Regas service income in FY21 was Rs23.07bn, while Gorgon volumes in Dahej in Q4 was 9tbtu. Inventory gain in Q4 was minor at Rs40mn. Other Income in Q3FY21 included Rs110mn of dividend income.

#### Comments by CEO Akshay Kumar Singh in media

- Dahej plant on India's West Coast is being expanded to 22.5mmtpa from 17.5mmtpa now; utilization of Kochi terminal in Southern India can rise to 6.5mmtpa from 1.5mmtpa.
- Qatar is a preferred supplier because of proximity, but PLNG is not looking at investing in Qatar LNG projects; it is hopeful that Qatar will meet India's price expectations as India's gas requirement is guided by price.
- Current long-term contract with Qatar for 7.5mmtpa is valid until CY28. PLNG has time till Dec'2023 for a renewal. PLNG's agreement with Tellurian Inc. has expired and has not been extended.
- The company was forced to cut Dahej terminal utilization by 20% in April- May. Demand fall impacted processing of spot cargoes and had to defer a long-term cargo to June. Dahej utilization has now improved to 87%.

#### **Exhibit 5: DCF valuation**

DCF assumptions		Mar'23E (Rs mn)	
Risk Free Rate	6.0%	NPV Of FCF	224,503
Risk Premium	5.5%	Terminal Value	468,498
Beta	0.85	PV Of TV	180,971
Cost Of Equity	10.7%	Total Value	405,473
Cost Of Debt	9.5%	Less: Net Debt (Y/E)	-29,341
Post Tax Cost Of Debt	7.1%	Equity Value	434,814
Average Debt:Equity Ratio	19.5%	No. Of Shares O/S (mn)	1,500
WACC	10.0%	Target Price (Rs)	290
Terminal Growth Rate	0.0%		

Source: Company, Emkay Research

#### Exhibit 6: PE-based valuation

Rs	FY19	FY20	FY21	FY22E	FY23E	FY24E
Adjusted EPS	14.9	17.2	19.7	18.4	20.4	21.1
Target Multiple (x)					15.0	
DCF Target Price					290	

Source: Company, Emkay Research

# Key Financials (Standalone)

# Income Statement

Y/E Mar (Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Revenue	354,520	260,229	349,187	405,502	418,251
Expenditure	311,861	213,234	305,063	356,555	366,457
EBITDA	42,659	46,995	44,124	48,947	51,794
Depreciation	7,761	7,841	8,276	9,476	11,333
EBIT	34,898	39,155	35,848	39,471	40,461
Other Income	3,726	3,882	4,200	4,860	5,524
Interest expenses	4,032	3,360	3,244	3,394	3,699
PBT	34,592	39,677	36,805	40,937	42,287
Тах	5,232	10,183	9,275	10,316	10,656
Extraordinary Items	(3,485)	0	0	0	0
Minority Int./Income from Assoc.	0	0	0	0	0
Reported Net Income	26,976	29,494	27,530	30,621	31,631
Adjusted PAT	25,875	29,494	27,530	30,621	31,631

# Balance Sheet

Y/E Mar (Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Equity share capital	15,000	15,000	15,000	15,000	15,000
Reserves & surplus	94,530	101,495	112,507	126,286	142,102
Net worth	109,530	116,495	127,507	141,286	157,102
Minority Interest	0	0	0	0	0
Loan Funds	52,984	48,392	47,984	51,680	55,530
Net deferred tax liability	8,883	8,806	8,738	8,669	8,600
Total Liabilities	171,397	173,693	184,229	201,636	221,232
Net block	111,882	103,131	95,959	88,089	78,366
Investment	3,491	15,496	15,634	15,774	15,915
Current Assets	71,570	70,445	90,303	107,239	125,618
Cash & bank balance	44,320	43,423	54,309	65,353	81,964
Other Current Assets	3,085	1,864	2,237	2,684	3,221
<b>Current liabilities &amp; Provision</b>	15,593	15,633	22,421	26,221	26,922
Net current assets	55,978	54,811	67,882	81,018	98,696
Misc. exp	0	0	0	0	0
Total Assets	171,397	173,693	184,229	201,636	221,232

## **Cash Flow**

Y/E Mar (Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
PBT (Ex-Other income) (NI+Dep)	30,866	35,795	32,604	36,077	36,763
Other Non-Cash items	(489)	292	0	0	0
Chg in working cap	(3,548)	193	(2,253)	(2,161)	(1,137)
Operating Cashflow	33,462	35,592	32,979	36,856	40,391
Capital expenditure	(39,557)	702	(5,603)	(13,606)	(13,109)
Free Cash Flow	(6,095)	36,294	27,376	23,250	27,281
Investments	6,402	(12,005)	(139)	(140)	(141)
Other Investing Cash Flow	21,024	(1,481)	0	0	0
Investing Cashflow	(8,405)	(8,903)	(1,542)	(8,886)	(7,726)
Equity Capital Raised	0	0	0	0	0
Loans Taken / (Repaid)	34,789	(4,592)	(408)	3,696	3,850
Dividend paid (incl tax)	(8,138)	(22,452)	(16,518)	(16,842)	(15,815)
Other Financing Cash Flow	(32,959)	2,817	(382)	(386)	(390)
Financing Cashflow	(10,339)	(27,586)	(20,552)	(16,926)	(16,054)
Net chg in cash	14,717	(897)	10,886	11,044	16,610
Opening cash position	29,603	44,320	43,423	54,309	65,353
Closing cash position	44,320	43,423	54,309	65,353	81,964

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Profitability (%)	FY20	FY21	FY22E	FY23E	FY24E
EBITDA Margin	12.0	18.1	12.6	12.1	12.4
EBIT Margin	9.8	15.0	10.3	9.7	9.7
Effective Tax Rate	15.1	25.7	25.2	25.2	25.2
Net Margin	8.3	11.3	7.9	7.6	7.6
ROCE	25.4	24.9	22.4	23.0	21.7
ROE	27.9	26.1	22.6	22.8	21.2
RoIC	32.8	32.9	32.0	37.0	40.7
Per Share Data (Rs)	FY20	FY21	FY22E	FY23E	FY24E
EPS	17.2	19.7	18.4	20.4	21.1
CEPS	24.7	24.9	23.9	26.7	28.6
BVPS	73.0	77.7	85.0	94.2	104.7
DPS	12.5	11.5	11.0	11.2	10.5
Valuations (x)	FY20	FY21	FY22E	FY23E	FY24E
PER	13.2	11.6	12.5	11.2	10.8
P/CEPS	10.0	10.0	10.4	9.3	8.7
P/BV	3.1	2.9	2.7	2.4	2.2
EV / Sales	1.0	1.3	0.9	0.8	0.7
EV / EBITDA	8.2	7.1	7.3	6.4	5.8
Dividend Yield (%)	5.5	5.0	4.8	4.9	4.6
Gearing Ratio (x)	FY20	FY21	FY22E	FY23E	FY24E
Net Debt/ Equity	0.0	(0.1)	(0.2)	(0.2)	(0.3)
Net Debt/EBIDTA	0.1	(0.2)	(0.5)	(0.6)	(0.8)
Working Cap Cycle (days)	7.8	13.3	13.2	13.1	13.1
Growth (%)	FY20	FY21	FY22E	FY23E	FY24E
Revenue	(7.7)	(26.6)	34.2	16.1	3.1
EBITDA	22.9	10.2	(6.1)	10.9	5.8
EBIT	14.0	12.2	(8.4)	10.1	2.5
PAT	25.2	9.3	(6.7)	11.2	3.3
			. ,		
Quarterly (Rs mn)	Q4FY20	Q1FY21	Q2FY21	Q3FY21	Q4FY21
Quarterly (Rs mn) Revenue	<b>Q4FY20</b> 85,672	<b>Q1FY21</b> 48,836	<b>Q2FY21</b> 62,358	<b>Q3FY21</b> 73,282	<b>Q4FY21</b> 75,753
<b>Quarterly (Rs mn)</b> Revenue EBITDA	<b>Q4FY20</b> 85,672 6,975	<b>Q1FY21</b> 48,836 9,099	<b>Q2FY21</b> 62,358 13,632	<b>Q3FY21</b> 73,282 13,353	<b>Q4FY21</b> 75,753 10,911
Quarterly (Rs mn) Revenue EBITDA EBITDA Margin (%)	Q4FY20 85,672 6,975 8.1	Q1FY21 48,836 9,099 18.6	Q2FY21 62,358 13,632 21.9	Q3FY21 73,282 13,353 18.2	<b>Q4FY21</b> 75,753 10,911 <b>14.4</b>
Quarterly (Rs mn) Revenue EBITDA EBITDA Margin (%) PAT	Q4FY20 85,672 6,975 8.1 3,590	Q1FY21 48,836 9,099 18.6 5,202	Q2FY21 62,358 13,632 21.9 9,273	Q3FY21 73,282 13,353 18.2 8,785	<b>Q4FY21</b> 75,753 10,911 <b>14.4</b> 6,234
Quarterly (Rs mn) Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs)	Q4FY20 85,672 6,975 8.1	Q1FY21 48,836 9,099 18.6	Q2FY21 62,358 13,632 21.9	Q3FY21 73,282 13,353 18.2	<b>Q4FY21</b> 75,753 10,911 <b>14.4</b> 6,234
Quarterly (Rs mn) Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs) Source: Company, Emkay Research	Q4FY20 85,672 6,975 8.1 3,590	Q1FY21 48,836 9,099 18.6 5,202	Q2FY21 62,358 13,632 21.9 9,273	Q3FY21 73,282 13,353 18.2 8,785	Q4FY21 75,753 10,911 14.4 6,234 4.2
Quarterly (Rs mn) Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs) Source: Company, Emkay Research Shareholding Pattern (%)	Q4FY20 85,672 6,975 8.1 3,590 2.4	Q1FY21 48,836 9,099 18.6 5,202 3.5	Q2FY21 62,358 13,632 21.9 9,273 6.2	Q3FY21 73,282 13,353 18.2 8,785 5.9	Q4FY21 75,753 10,911 14.4 6,234 4.2 Mar-21
PAT Quarterly (Rs mn) Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs) Source: Company, Emkay Research Shareholding Pattern (%) Promoters FIIs	Q4FY20 85,672 6,975 8.1 3,590 2.4 Mar-20	Q1FY21 48,836 9,099 18.6 5,202 3.5 Jun-20	Q2FY21 62,358 13,632 21.9 9,273 6.2 Sep-20	Q3FY21 73,282 13,353 18.2 8,785 5.9 Dec-20	3.3 Q4FY21 75,753 10,911 14.4 6,234 4.2 Mar-21 50.0 30.5
Quarterly (Rs mn) Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs) Source: Company, Emkay Research Shareholding Pattern (%) Promoters	Q4FY20 85,672 6,975 8.1 3,590 2.4 Mar-20 50.0	Q1FY21 48,836 9,099 18.6 5,202 3.5 Jun-20 50.0	Q2FY21 62,358 13,632 21.9 9,273 6.2 Sep-20 50.0	Q3FY21 73,282 13,353 18.2 8,785 5.9 Dec-20 50.0	Q4FY21 75,753 10,911 14.4 6,234 4.2 Mar-21 50.0


Source: Capitaline


#### RECOMMENDATION HISTORY TABLE

Date	Closing Price	TP	Period (months)	Rating	Analyst
29-May-21	241	340	12m	Buy	Sabri Hazarika
23-Apr-21	235	340	12m	Buy	Sabri Hazarika
23-Mar-21	230	340	12m	Buy	Sabri Hazarika
12-Feb-21	242	340	12m	Buy	Sabri Hazarika
21-Jan-21	246	300	12m	Buy	Sabri Hazarika
12-Nov-20	236	300	12m	Buy	Sabri Hazarika
28-Sep-20	216	300	12m	Buy	Sabri Hazarika
18-Aug-20	250	300	12m	Buy	Sabri Hazarika
30-Jun-20	244	290	12m	Hold	Sabri Hazarika
6-May-20	220	305	12m	Hold	Sabri Hazarika
11-Feb-20	249	305	12m	Hold	Sabri Hazarika
24-Jan-20	261	315	12m	Hold	Sabri Hazarika
4-Dec-19	260	315	12m	Hold	Sabri Hazarika
30-Oct-19	264	315	12m	Buy	Sabri Hazarika
29-Oct-19	258	300	12m	Buy	Sabri Hazarika
25-Oct-19	251	300	12m	Buy	Sabri Hazarika
24-Sep-19	237	300	12m	Buy	Sabri Hazarika
23-Sep-19	234	300	12m	Buy	Sabri Hazarika
8-Aug-19	218	285	12m	Buy	Sabri Hazarika
10-Jun-19	217	285	12m	Buy	Sabri Hazarika
16-May-19	204	285	12m	Buy	Sabri Hazarika
22-Mar-19	220	290	12m	Buy	Sabri Hazarika
2-Feb-19	201	290	12m	Buy	Sabri Hazarika
28-Jan-19	199	300	12m	Buy	Sabri Hazarika
24-Jan-19	206	300	12m	Buy	Sabri Hazarika
31-Dec-18	204	305	12m	Buy	Sabri Hazarika
11-Dec-18	188	305	12m	Buy	Sabri Hazarika
5-Nov-18	193	305	12m	Buy	Sabri Hazarika
4-Sep-18	206	305	12m	Buy	Sabri Hazarika
28-Aug-18	201	305	12m	Buy	Sabri Hazarika
27-Jul-18	201	305	12m	Buy	Sabri Hazarika
13-Jul-18	184	305	12m	Buy	Sabri Hazarika

Source: Company, Emkay Research

RECOMMENDATION HISTORY CHART







# Analyst: Sabri Hazarika

#### **Contact Details**

sabri.hazarika@emkayglobal.com +91 22 6612 1282

#### Sector

Oil & Gas

#### Analyst bio

Sabri Hazarika holds an MBA and comes with 12 years of research experience. His team currently covers 12 stocks in the Indian Oil & Gas space.

# Emkay Alpha Portfolio – Oil & Gas

#### EAP sector portfolio

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight (Normalised)
Oil & Gas	10.48	10.48	0%	0	100.00
BPCL	0.43	0.46	5%	2	4.35
GAIL	0.34	0.37	10%	3	3.54
Gujarat Gas	0.11	0.00	-100%	-11	0.00
Gujarat State Petronet	0.10	0.09	-8%	-1	0.85
Gulf Oil Lubricants	0.00	0.00	NA	0	0.00
HPCL	0.24	0.23	-4%	-1	2.23
Indian Oil	0.33	0.36	10%	3	3.45
Indraprastha Gas	0.21	0.23	11%	2	2.18
Petronet LNG	0.21	0.20	-2%	0	1.94
Oil India	0.06	0.06	1%	0	0.54
ONGC	0.51	0.56	10%	5	5.30
Reliance Industries	7.95	7.92	0%	-3	75.60
Cash	0.00	0.00	NA	0	0.02

Source: Emkay Research

\* Not under coverage: Equal Weight

High Conviction/Strong Over Weight

## Sector portfolio NAV

Base					Latest
1-Apr-19	9-Jun-20	8-Dec-20	9-Mar-21	7-May-21	8-Jun-21
100.0	99.2	123.6	137.3	124.1	141.5
100.0	99.4	122.7	136.4	123.5	140.8
	<b>1-Apr-19</b> 100.0	1-Apr-19         9-Jun-20           100.0         99.2	1-Apr-19         9-Jun-20         8-Dec-20           100.0         99.2         123.6	1-Apr-19         9-Jun-20         8-Dec-20         9-Mar-21           100.0         99.2         123.6         137.3	1-Apr-19         9-Jun-20         8-Dec-20         9-Mar-21         7-May-21           100.0         99.2         123.6         137.3         124.1


\*Performance measurement base date 1<sup>st</sup> April 2019 Source: Emkay Research

#### Price Performance (%)

	1m	3m	6m	12m
EAP - Oil & Gas	14.0%	3.0%	14.4%	42.7%
BSE200 Neutral Weighted Portfolio (ETF)	14.0%	3.2%	14.8%	41.7%

Source: Emkay Research





Source: Emkay Research

## Please see our model portfolio (Emkay Alpha Portfolio): Nifty

#### Please see our model portfolio (Emkay Alpha Portfolio): SMID

"Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals"

# **Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
BUY	Over 15%
HOLD	Between -5% to 15%
SELL	Below -5%

Completed Date: 10 Jun 2021 03:26:11 (SGT) Dissemination Date: 10 Jun 2021 03:27:11 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

#### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

• This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.

• Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

**Disclaimer for U.S. persons only:** This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

#### ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate<sup>1</sup> does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

#### COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of June 10, 2021
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report
- Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of June 10, 2021.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the June 10, 2021
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the June 10, 2021

General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 <sup>th</sup> Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

# Emkay Global Financial Services Ltd. CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com